IKNA News and Press, Ikena Oncology Inc. From 11/28/22

Novel best-in-class MEK-RAF complex inhibitor IK-595 targets RAS pathway; IND in 2023 Novel paralog-selective TEAD inhibitor IK-930 advancing as planned in dose escalation; clinical data in 2023 Company prioritizes advancement of targeted oncology portfolio; cash runway ...

BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will present a corporate overview and participate in 1x1 investor mee...

IK-175 combined with nivolumab showed durable antitumor activity with a 20% ORR and 40% DCR in heavily pretreated urothelial carcinoma IK-175 monotherapy activity observed; confirmed partial response with DoR of 14.9 months and ongoing Program in collaboration with Bristol...

Initial clinical data of AHR antagonist, IK-175, shows treatment is well-tolerated and demonstrates anti-tumor activity both as a monotherapy and in combination with nivolumab IK-930, lead targeted oncology program, progressing as planned, advanced through multiple dose escalati...

Ikena Oncology press release ( NASDAQ: IKNA ): Q3 GAAP EPS of -$0.48 beats by $0.01 . Revenue of $6.4M (+70.7% Y/Y) beats by $2.08M . As of September 30, 2022, Ikena had $174.4 million in cash, cash equivalents, and marketable securities, and believes this will...

Initial clinical data of AHR antagonist, IK-175, shows treatment is well-tolerated and demonstrates anti-tumor activity both as a monotherapy and in combination with nivolumab Progressing lead targeted oncology program in TEAD inhibition with IK-930; advanced through multiple do...

BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced a poster presentation highlighting preclinical data on the company’s novel TEA...

Clinical collaboration with AstraZeneca announced for the evaluation of osimertinib in combination with IK-930 for patients with EGFR-mutant lung cancers Company shares further detail on the differentiators of IK-930, a TEAD-paralog selective inhibitor BOSTON, Oct. 18, 202...

BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that two abstracts highlighting the company’s Aryl Hydrocarbon Receptor (AHR) ...

BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in two upcoming investor conferences in New York, N...